Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)

13 Investigator sites, Palo Alto

4 Investigator sites, Buenos Aires

6 Investigator sites, Melbourne

3 Investigator sites, Minsk

4 Investigator sites, Brussels

7 Investigator sites, Québec

6 Investigator sites, Prague

2 Investigator sites, Jyväskylä

2 Investigator sites, Saint-Priest-en-Jarez

5 Investigator sites, Aachen

5 Investigator sites, Athens

2 Investigator sites, Milan

2 Investigator sites, Lodz

4 Investigator sites, Gyeonggi-do

4 Investigator sites, Barcelona

3 Investigator sites, Uppsala

3 Investigator sites, Kayseri

6 Investigator sites, Leicester